EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan

Fei-Hung Hung, Hung-Pin Peng, Chen-Fang Hung, Ling-Ling Hsieh, An-Suei Yang, Yong Alison Wang iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Fei-Hung Hung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Mismatch Repair, MutL Protein Homolog 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Promotion Administration, Ministry of Health and Welfare, Taipei Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying Lynch syndrome significantly impacts cancer risk management, treatment, and prognosis. Validation of mutation risk predictive models for mismatch repair (MMR) genes is crucial for guiding genetic counseling and testing, particularly in the understudied Asian population. We evaluated the performance of four MMR mutation risk predictive models in a Chinese cohort of 604 patients with colorectal cancer (CRC), endometrial cancer (EC), or ovarian cancer (OC) in Taiwan. All patients underwent germline genetic testing and 36 (6.0%) carried a mutation in the MMR genes ( MLH1 , MSH2 , MSH6 , and PMS2 ). All models demonstrated good performance, with area under the receiver operating characteristic curves comparable to Western cohorts: PREMM 5 0.80 (95% confidence interval [CI], 0.73–0.88), MMRPro 0.88 (95% CI, 0.82–0.94), MMRPredict 0.82 (95% CI, 0.74–0.90), and Myriad 0.76 (95% CI, 0.67–0.84). Notably, MMRPro exhibited exceptional performance across all subgroups regardless of family history (FH+ 0.88, FH‐ 0.83), cancer type (CRC 0.84, EC 0.85, OC 1.00), or sex (male 0.83, female 0.90). PREMM 5 and MMRPredict had good accuracy in the FH+ subgroup (0.85 and 0.82, respectively) and in CRC patients (0.76 and 0.82, respectively). Using the ratio of observed and predicted mutation rates, MMRPro and PREMM 5 had good overall fit, while MMRPredict and Myriad overestimated mutation rates. Risk threshold settings in different models led to different positive predictive values. We suggest a lower threshold (5%) for recommending genetic testing when using MMRPro, and a higher threshold (20%) when using PREMM 5 and MMRPredict. Our findings have important implications for personalized mutation risk assessment and counseling on genetic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairMutL Protein Homolog 1AdultAgedFemaleHumansMaleMiddle AgedCohort StudiesDNA-Binding ProteinsEast Asian PeopleEndometrial NeoplasmsGenetic TestingGerm-Line MutationMismatch Repair Endonuclease PMS2MutationMutS Homolog 2 ProteinOvarian NeoplasmsTaiwan

Stichwörter der Autor:innen

Lynch syndromeMMR mutation risk predictioncancer risk managementgenetic counseling

Substanzen

DNA-Binding ProteinsG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, human

Autor:innen und Institutionen

  • Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan.
  • Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Department of Research, Koo Foundation Sun-Yat Sen Cancer Center, Taipei, Taiwan.
  • Department of Internal Medicine, Koo Foundation Sun-Yat Sen Cancer Center, Taipei, Taiwan.
  • Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

ORCID-Profile: Yong Alison Wang

Förderung

  • Health Promotion Administration, Ministry of Health and Welfare
  • Taipei Medical University

Zitieren

APA

Hung, F. H., Peng, H. P., Hung, C. F., Hsieh, L. L., Yang, A. S., & Wang, Y. A. (2024). Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan. International Journal of Cancer. https://doi.org/10.1002/ijc.35106

Vancouver

Hung FH, Peng HP, Hung CF, Hsieh LL, Yang AS, Wang YA. Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan. International Journal of Cancer. 2024. doi:10.1002/ijc.35106

BibTeX
@article{Hung2024,
  author = {Hung, Fei-Hung and Peng, Hung-Pin and Hung, Chen-Fang and Hsieh, Ling-Ling and Yang, An-Suei and Wang, Yong Alison},
  title = {Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35106}
}
Kostenlos starten →